Faculty: Brent E. Korba

Dr. Korba is a Research Professor at the Department of Microbiology & Immunology

  • Ph.D., University of Maryland Baltimore County, 1981
  • At Georgetown since: 1984
  • Current lab has capacity for both new PhD students and Post Doctoral Fellows
  • Contact: korbabe@georgetown.edu
Research Area(s)

The laboratory is focused on antiviral therapies against hepatitis B and C viruses using a variety of cell culture and enzyme-based technologies. Investigations examine a wide range of parameters (DNA, RNA, proteins), both viral and cellular utilizing a variety of molecular biology-based techniques. Studies extend from basic screening (e.g. drug discovery) to mechanisms of action.

Until recently, Dr. Korba was part opf the research faculty within the Division of Molecular Virology at the Dept of Microbilogy & Immunology in Rockville, MD. DMVI faculty and research staff have now permanently relocated to the Washington, DC Georgetown University Medical Center Campus.

Over the years, members of the DMVI laboratory have conducted investigations, often involving collaborations with various NIAID scientists, grantees and contractors, in projects involving rhinoviruses, mouse hepatitis virus, influenza viruses (equine and human), parainfluenza 1, 2 & 3 viruses, measles virus, virions of progressive multifocal leukoencephalopathy, agents of nonbacterial gastroenteritis (Norwalk agent and rotaviruses), adenoviruses, vaccinia virus, respiratory syncytial virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, woodchuck hepatitis virus, human immunodeficiency virus, simian immunodeficiency virus, feline immunodeficiency virus, human herpesvirus-6 and human herpesvirus-7. 

The research efforts have ranged from basic virology to studies aimed at defining the natural history of infection and disease, diagnostic methodology, prevention by passive and active immunization and treatment. These activities have resulted in many publications in the scientific literature.

  • Li C, Prichard MN, Korba BE, Drach JC, Zemlicka J. Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine. Bioorg Med Chem. 2008 Mar 1;16(5):2148-55. Epub 2007 Dec 5.
  • Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.
  • Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, Korba BE, Aldern KA, Beadle JR, Hostetler KY. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother. 2007 Oct;51(10):3505-9. Epub 2007 Jul 23. Erratum in: Antimicrob Agents Chemother. 2007 Dec;51(12):4538.
  • Vlassov AV, Korba B, Farrar K, Mukerjee S, Seyhan AA, Ilves H, Kaspar RL, Leake D, Kazakov SA, Johnston BH. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA. Oligonucleotides. 2007 Summer;17(2):223-36.
  • Zhang P, Zhang N, Korba BE, Hosmane RS. Structure-activity relationship studies on anti-HCV activity of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2225-8. Epub 2007 Feb 2.
  • Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol. 2007 Jan;22(1):86-91.
  • Choo H, Beadle JR, Kern ER, Prichard MN, Keith KA, Hartline CB, Trahan J, Aldern KA, Korba BE, Hostetler KY. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters. Antimicrob Agents Chemother. 2007 Feb;51(2):611-5. Epub 2006 Nov 27.
  • Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther. 2006 Aug;4(4):549-61. Review.
  • Zhang P, Zhang N, Korba BE, Hosmane RS. Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5397-401. Epub 2005 Oct 5.
  • Casey J, Cote PJ, Toshkov IA, Chu CK, Gerin JL, Hornbuckle WE, Tennant BC, Korba BE. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother. 2005 Oct;49(10):4396-9.

Medline publications list